FCG
JAZZ icon

Fielder Capital Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Fielder Capital Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$297K Buy
1,569
+40
+3% +$6.99K 0.06% 193
2025
Q4 		$260K Buy
+1,529
New +$234K 0.06% 216

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fielder Capital Group's JAZZ Position: Q1 2026 in Review

Fielder Capital Group increased its Jazz Pharmaceuticals (JAZZ) stake by 2.6% in Q1 2026, buying an estimated $6.99K and bringing the position to 1,569 shares worth $297K. The position accounts for 0.06% of the portfolio, ranked #193.

Fielder Capital Group first reported a position in JAZZ in Q4 2025 and has held it in 2 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Fielder Capital Group held 1,569 shares of Jazz Pharmaceuticals worth $297K as of Q1 2026.
  • Fielder Capital Group bought 40 Jazz Pharmaceuticals shares in Q1 2026, an estimated $6.99K.
  • Jazz Pharmaceuticals made up 0.06% of Fielder Capital Group's portfolio in Q1 2026, its #193 holding.
  • Fielder Capital Group first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Fielder Capital Group's 13F filing for Q1 2026, filed 12 May 2026.